Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): Potential role in breast cancer

Seminars in Oncology

Volumn 30, Issue 2 SUPPL. 3, 2003, Pages 30-33

  Roychowdhury, Debasish ^a   Lahn, Michael ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 3521; PROTEIN KINASE C ALPHA; TUMOR PROMOTER;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; BREAST CARCINOGENESIS; CELL ACTIVATION; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; NAUSEA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR CELL LINE; VOMITING;

EID: 0037397817     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.37273     Document Type: Conference Paper

References (33)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 2001
3. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661-665, 1988
4. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59:257-280, 1993
5. Schenk PW, Snaar-Jagalska BE: Signal perception and transduction: The role of protein kinases. Biochim Biophys Acta 1449:1-24, 1999
6. Blobe GC, Obeid LM, Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13:411-431, 1994
7. Yuspa SH: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis - Thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res 54:1178-1189, 1994
8. Ways DK, Kukoly CA, deVente J, et al: MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95:1906-1915, 1995
9. Henttu P, Vihko P: The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. Biochem Biophys Res Commun 244:167-171, 1998
10. Perletti GP, Smeraldi C, Porro D, et al: Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells. Biochem Biophys Res Commun 205:1589-1594, 1994
11. Adesina AM, Dooley N, Yong VW, et al: Differential role for protein kinase C-mediated signaling in the proliferation of medulloblastoma cell lines. Int J Oncol 12:759-768, 1998
12. Cho KK, Mikkelsen T, Lee YJ, et al: The role of protein kinase C alpha in U-87 glioma invasion. Int J Dev Neurosci 17:447-461, 1999
13. O'Brian C, Vogel VG, Singletary SE, et al: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49:3215-3217, 1989
14. Helene C, Toulme JJ: Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99-125, 1990
15. Calabretta B: Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 51:4505-4510, 1991
16. Crooke ST: Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376, 1992
17. Crooke ST, Bennett CF: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107-129, 1996
18. Crooke ST: Antisense Drug Technology: Principles, Strategies, and Applications. New York, NY, Marcel Dekker, 2001
19. Dean NM, McKay R, Condon TP, et al: Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269:16416-16424, 1994
20. Dean NM, McKay R: Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 91:11762-11766, 1994
21. Dennis JU, Dean NM, Bennett CF, et al: Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett 128:65-70, 1998
22. Yazaki T, Ahmad S, Chahlavi A, et al: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 50:236-242, 1996
23. Advani R, Fisher GA, Grant P, et al: A phase I trial of an antisense oligonucleotide targeted to protein kinase C-(ISIS 3521/ISI 641A) delivered as a 24-hour continuous infusion (CI). Proc Am Soc Clin Oncol 18:158a, 1999 (abstr)
24. Cripps MC, Figueredo AT, Oza AM, et al: Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada Clinical Trials Group study. Clin Cancer Res 8:2188-2192, 2002
25. Emmanouilides CE, Saleh A, Laufman L, et al: Phase II trial of the efficacy and safety of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, in patients with low-grade, non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 21:282a, 2002 (abstr 1124)
26. Mani S, Rudin CM, Kunkel K, et al: Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 8:1042-1048, 2002
27. Moore MR, Saleh M, Jones CM, et al: Phase II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, with docetaxel in NSCLC. Proc Am Soc Clin Oncol 21:297a, 2002 (abstr 1186)
28. Nemunaitis J, Holmlund JT, Kraynak M, et al: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17:3586-3595, 1999
29. Ritch P, Belt R, George S, et al: Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, with cisplatin and gemcitabine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 21:309a, 2002 (abstr 1233)
30. Yuen AR, Halsey J, Fisher GA, et al: Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5:3357-3363, 1999
31. Yuen AR, Halsey J, Lum B, et al: Phase I/II Trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 20:309a, 2001 (abstr 1232)
32. Isis Pharmaceuticals Inc: LY900003 Clinical Investigator's Brochure. Carlsbad, CA, Isis Pharmaceuticals, Revision 8. 2-28-0002
33. Gradishar WJ, O'Neill A, Cobleigh M, et al: A phase II trial with antisense oligonucleotide ISIS 3521/CGP 64128a in patients with metastatic breast cancer: ECOG trial 3197. Proc Am Soc Clin Oncol 20:44a, 2001 (abstr 171)